IHD presents results of IHD-Amy
blood tests for Alzheimer's disease
20 July 2011
Innovative Health Diagnostics (IHD), has presented the
first clinical results for its IHD-Amy blood test that can detect Alzheimer's
disease from a very small blood sample.
The test makes it possible to have a diagnostic
test based on a peripheral biochemical marker, which is therefore
straightforward and economic to carry out. This makes it one of the most
promising ways forward in the research into the diagnosis of Alzheimer's
In addition, the fact that this kind of test is carried
out at an early stage means that treatment can be followed through far
more efficiently, and also means that patient hospitalisation can be
delayed. On a longer term basis, this kind of test could be a useful
diagnostic tool and a crucial element of the establishment of a
proactive public health policy initiative.
The development of these tests is made possible by recent advances in
medical knowledge and the discovery of fluorescent probes that can
detect proteins that are specific to the disease. Just one drop of blood
— 100 to 200 micro litres — is enough to carry out an analysis. These
blood tests have the advantage of being quick, minimally invasive, and
economic to carry out: just like the IHD-Amy test.
The specific IHD-Amy test
Using just one drop of blood, this test can identify the interaction
that takes place between a peptide (peptide b-amyloid 1-42) and the red
blood cell membranes using a peptide fluorescent probe. This interaction
takes place in patients who have Alzheimer's disease.
This test is very
specific to the disease as it detects a significant major protein from
the time it appears and throughout its evolution. The proof of concept
for this test was obtained following a first clinical trial which was
concluded at the end of 2010. Additionally it has been successfully
performed on animal models of the disease. The test also could enable
early detection and monitoring of the disease if it targets the amyloid
The IHD-Amy yielded comparable performances on cellular and animal
models of Alzheimer's disease, making it a very high-performing tool for
pharmaceutical manufacturers for the approval of preclinical and
clinical phase medicines of the future.
IHD President Xavier Regnaut commented: "The results of our study
with IHD-Amy demonstrate that this is one of the best performing tests
around, which validates its real potential as a diagnostic aid tool for
doctors in the future. These first results are
very promising, and the clinical development schedule that we are
working to should mean that we can confirm these results in the coming
The clinical study was carried out in partnership with Colmar Civil
Hospitals between June and December 2010. The study was carried out on
108 samples that included 32 healthy volunteers, 58 people with
Alzheimer's disease, and 18 people with multiple sclerosis.
Patient inclusion criteria were as follows:
- the healthy volunteers to be roughly the same age as the
patients with Alzheimer's disease, and should not present any
psychiatric case history nor be under any medication that might
negatively affect their cognitive functions.
- the patients with Alzheimer's disease at the Alsace Consultation
Mémoire de Ressource et de Recherche (CM2R) Unit of Colmar Civil
Hospitals Unit that deals with research into Alzheimer's disease are
to demonstrate a likelihood of a diagnosis of Alzheimer's disease in
accordance with NINCDS-ADRDA (McKhann G, 1984) criteria based on a
clinical examination, medical imaging examination and neuro-psychological
- Patients with at least a chronic inflammatory syndrome such as
multiple sclerosis are diagnosed on the basis of clinical,
biological (analysis of cerebrospinal fluid) and medical imaging (IRM)
Alzheimer's disease is one of the major public health issues to have
been identified as a national priority in a number of countries, eminent
among them France, which has implemented the Alzheimer plan (2008-2012).
Alzheimer's disease is the most common cause of senile dementia, with a
prevalence of the pathology of 25% of people over the age of 65. The
situation is all the more worrying given that up to now no curative
treatment has been available, even as the number of patients with the
disease increases year on year.
- 35.6 million people worldwide have Alzheimer's disease, a figure
which is predicted to increase to 115.4 people by 2050 (World
Alzheimer Report 2010, Alzheimer's disease International).
- 2 million new cases a year of the disease are being identified
in North America and Europe, where 15 million people suffer from the
pathology. Over the next 20 years, this figure is expected to
- Given that populations in emerging countries are increasingly
living a more westernised lifestyle, this number is already
Innovative Health Diagnostics >>